Day: November 10, 2022

Third Quarter Financial Results (in thousands) Q3 22 Q3 21 YOYChange Q3 22YTD Q3 21YTD YOYChangeTotal Revenues $ 16,264   $ 15,109   7.6 % $ 50,513   $ 41,595   21.4 %Operating Income   671     1,018   (34.1 %)   2,585     2,009   28.7 %Income Before Provision for Taxes   776     1,473   (47.3 %)   2,789     5,190   (46.3 %)Net Income   1,887     1,153   (63.7 %)   3,547     4,495   (21.1 %)EBITDA*   820     1,711   (52.1 %)   2,944     5,979   (50.8 %)Adjusted EBITDA*   768     1,251   (38.6 %)   2,898     2,755   5.2 %Pre-Corporate EBITDA*   1,015     1,451   (30.0 %)   3,621     3,398   6.6 %* Non-GAAP measures referenced are detailed in the disclosures at the end of this release.DALLAS, Nov. 10, 2022 (GLOBE NEWSWIRE) — Wilhelmina International, Inc. (Nasdaq:WHLM) (“Wilhelmina” or...

CARLSBAD, Calif., Nov. 10, 2022 (GLOBE NEWSWIRE) — AppTech Payments Corp. (“AppTech”) (NASDAQ: APCX), a Fintech company powering commerce experiences, today announced results for the three months ended September 31, 2022. The financial statements and 10-Q are available on sec.gov. Third Quarter 2022 Financial HighlightsRevenue for the three months ended on September 30, 2022 was approximately $115 thousand versus $92 thousand for 3Q21. Cash balance as of September 31, 2022 was $5.9 million.Recent Business HighlightsUnveiled its new product platform, Commerse™ at Money20/20 USA. Cloud-based Commerce Experiences-as-a-Service (“CXS”) platform is backed by AppTech’s mobile commerce patents, core partner technology and other related internal intellectual property. CXS solutions incorporate PaaS, BaaS, Data,...

Initial clinical data for VOR33 on track for Q4 2022 Eyal C. Attar, M.D. appointed as Chief Medical Officer Initiated in-house clinical manufacturing at Cambridge, MA headquartersCAMBRIDGE, Mass., Nov. 10, 2022 (GLOBE NEWSWIRE) — Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today reported financial results for the three-month period ended September 30, 2022 and provided a business update.  “We continue to actively enroll patients in our lead clinical trial, VBP101 and look forward to sharing important initial clinical proof of concept data from this study by year end,” said Dr. Robert Ang, Vor Bio’s President and Chief Executive Officer. “We are excited that our new in-house clinical manufacturing facility is now operational and our IND for VCAR33 is on-track for submission in the first half of...

JERUSALEM, Nov. 10, 2022 (GLOBE NEWSWIRE) — Entera Bio Ltd. (NASDAQ: ENTX), (“Entera” or the “Company”) a leader in the development of orally delivered peptides and therapeutic proteins, today announced its financial results for the third quarter of 2022 and provided the following corporate updates. Corporate Updates: Achieved FDA Agreement for Pivotal Study of EB613, the World’s First Daily Bone Forming Oral PTH TabletOn October 6th, 2022, Entera announced that it had successfully completed its Type C meeting and reached a record agreement with the U.S. Food and Drug Administration (FDA) that a single pivotal Phase 3 placebo-controlled study could support a New Drug Application (NDA) submission for its lead clinical candidate, EB613 under the 505(b)(2) regulatory pathway. Importantly, the FDA also agreed that total hip bone...

Chart 1 Chart 1Chart 2 Chart 2SAN ANTONIO, Texas, Nov. 10, 2022 (GLOBE NEWSWIRE) — U.S. Global Investors, Inc. (NASDAQ: GROW) (the “Company”), a registered investment advisory firm with longstanding experience in global markets and specialized sectors from gold mining to emerging markets, today reported operating income of $1.6 million for the quarter ended September 30, 2022. The operating margin was a healthy 36% on total revenues of $4.4 million. The Company recorded net income of $118,000, or $0.01 per share. Average assets under management (AUM) for the three-month period ended September 30, 2022, were $2.9 billion, down approximately $1 billion from the same quarter last year. As of September 30, 2022, AUM was $2.3 billion, a decrease of approximately 46% from September 30, 2021. “U.S. investors continued to withdraw...

SAN DIEGO, Nov. 10, 2022 (GLOBE NEWSWIRE) — Histogen Inc. (NASDAQ: HSTO), a clinical-stage therapeutics company focused on developing both restorative therapeutics for orthopedic indications and pan-caspase and caspase selective inhibitors focused on treatments for infectious and inflammatory diseases, today reported financial results for the third quarter ended September 30, 2022 and provided an update on its clinical pipeline and other corporate developments. “We remain focused on the feasibility of developing emricasan as a potential treatment for bacterial skin infections including those related to methicillin resistant staphylococcus aureus (“MRSA”) and evaluating our caspase-1 inhibitors that impact the inflammasome pathway,” said Steven J. Mento, Ph.D., Interim President and Chief Executive Officer. “We also continue to...

AUSTIN, Texas, Nov. 10, 2022 (GLOBE NEWSWIRE) — Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM”), a clinical-stage biopharmaceutical company focused on the discovery and development of proprietary targeted biologic therapeutics, engineered toxin bodies (ETBs), to create novel therapies with potent and differentiated mechanisms of action for cancer and other serious diseases, today reported financial results and business updates for the third quarter of 2022. “We are excited with the progress we continue to make across all our clinical and pre-clinical programs. We have now seen evidence of monotherapy clinical activity with MT-6402, MT-5111, and MT-0169 in heavily pretreated relapsed/refractory patients — in both solid and hematological cancer settings — demonstrating the broad potential utility...

Announced first patient treated in Phase 1/2a clinical trial for CYNK-101 in first-line advanced HER2 positive gastric and gastroesophageal junction (G/GEJ) cancer Appointed Adrian Kilcoyne, M.D., M.P.H., M.B.A., as Chief Medical Officer and announced the promotion of two senior executives and the formation of a new Executive Committee Presenting an abstract at the Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting that supports the scientific rationale of the CYNK-101 Strengthened balance sheet using a combination of a $150 million at-the-market (ATM) facility and a $150 million pre-paid advance agreementFLORHAM PARK, N.J., Nov. 10, 2022 (GLOBE NEWSWIRE) — Celularity Inc. (Nasdaq: CELU) (Celularity), a clinical-stage biotechnology company developing placental-derived allogeneic cell therapies and biomaterial products,...